fda semaglutide warning news october 2025 Oral Approved to Reduce the Risk of Cardiovascular Events The U.S. health regulator asked

Measurement of -glutamylcysteine ligase (GCL) activity GCL activity was measured in lung and liver homogenates as previously described [18]

When used together, the products were reported to promote more GLP-1 receptor sites and reduce an enzyme that breaks down GLP-1 by 38 percent

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

Periodic breaks from peptide use enable baseline assessment and prevent potential desensitization, though evidence for desensitization with these peptides remains limited